Despite several small-molecule drugs that have revolutionized the current treatment strategy for acute myeloid leukemia (AML), hematopoietic stem cell transplantation remains the only curative treatment in most cases to date. Chimeric antigen receptor (CAR)-T cell therapy is one of the most promising...
In optimizing CAR-T cell therapy strategies for acute myeloid leukemia (AML), what key factors do you believe need to be comprehensively examined and considered? I think four aspects have to be considered to improve CAR-...
with immune checkpoint inhibitors such as anti-CD47 monoclonal antibodies enabling macrophages to target and eliminate AML cells. This approach enhances the immune system's attack on cancer cells by blocking immunosuppressive signals....
2021年11月,Hardikkumar Jetani等在BLOOD上发表文章“Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia”,阐述了唾液酸结合免疫球蛋白样凝集素(siglec)-6成为急性髓系白血病(AML)的CAR-T治疗靶点的可行性。 Siglec-6 is a novel target for CAR T-cell therapy in acute myeloi...
此外，经过精准编辑的细胞在体外和动物模型中均展现出了抵御CAR-T疗法攻击的能力，同时保持了其应有的功能，这一研究结果为降低AML治疗的在靶毒性提供了重要的可行性依据。综上所述，精准表位编辑技术在AML等恶性疾病的免疫治疗中展现出巨大的潜力，有望为患者的健康福祉带来更多可能。Wellhausen, N., O'Connell, R...
2023年10月5日，来自美国纪念斯隆凯特琳癌症中心的Michel Sadelain团队，在Cancer Cell期刊发表了题为Cooperative CAR targeting to selectively eliminate AML and minimize escape（共表达CAR嵌合受体选择性清除AML干细胞，防止其免疫逃逸）的文章。研究人员提出了一种CAR策略，可有效治疗AML并最小化对正常HSPC的毒性。他...
Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in AML has not recapitulated the efficacy seen in B cell malignancies. Here we rep
Dasatinib Plus CAR T-Cell Therapy Shows Efficacy in Ph+ Acute Lymphoblastic Leukemia March 27th 2025 Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc April 12th 2025 PROs, Gene Expression Vary Among Patients...
2023年10月5日,来自美国纪念斯隆凯特琳癌症中心的Michel Sadelain团队,在Cancer Cell期刊发表了题为Cooperative CAR targeting to selectively eliminate AML and minimize escape(共表达CAR嵌合受体选择性清除AML干细胞,防止其免疫逃逸)的文章。研究人员提出了一种CAR策略,可有效治疗AML并最小化对正常HSPC的毒性。他们构建...
CAR-T新靶点—AML 近日,来自德克萨斯大学西南医学中心的研究团队在权威学术期刊《Molecular Therapy》上发表了一项关于CAR-T治疗AML的最新进展,论文题目为“A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML”。 其中,文章的通讯作者是来自德克萨斯大学西南医学中心的Chengcheng Zhang教授。张教授毕...